ASCO 2020：11项华北地区研究入选口头报告，17项Poster报告

颇受全球另行冠疫情影响，原定于5年末29日~6年末2日在芝加哥举办地的新泽西州病理学会（ASCO）该协会来年将首次以线上方式举办，这是现有最大规模的线上盛宴。那时候，内阁会议的简短解答公布，共103个sessions，里国总共11项研究工作表现出色口头报告，17项表现出色Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他松可用HER2+移到病态乳腺肿腺（PHOEBE）：一项III期随机试验病态。

第二场：移到病态乳腺肿腺

笔记：里国医学科学院的医院徐兵河大学教授、马飞大学教授，复旦大学附属的医院胡夕春大学教授等

简短号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阳病态乳腺肿腺标准规范疗程后卡培他松维持节拍低剂量的III期试验病态（SYSUCC-001）。

第二场：乳腺肿腺—均匀分布/周围/基本功能疗程

笔记：北京大学禁毒里心君树森大学教授等

简短号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用移到病态脑干的表型特征来预测脑干脊液里周而复始DNA检测的概率: 另行工具对抗老对手

第二场：另行工具解决老问题

笔记：杨美芹 杨德兰等

简短号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

利诺非尼对瓦努阿图拉非尼作为后期肝细胞核肿腺的中卫疗程：一项新开表单、随机、多里心II/III期试验病态。

第二场：消化系统肿腺—消化道食管、凋亡和绝

笔记：南京大学毛脉的医院毕锋大学教授、里国团结解放军南开的医院秦叔逵大学教授等

简短号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

里国后期肝肿腺症状阿帕替尼二线疗程：一项随机、双盲依此、双盲III期研究工作

第二场：消化系统肿腺—消化道食管、凋亡和绝

笔记：里国团结解放军南开的医院秦叔逵大学教授、南京大学毛脉的医院杨秋大学教授等

简短号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后期患上病态卵巢肿腺二次细胞核减灭术的一项随机III期试验病态：SOC1 / SGOG-OV2。

专题：外科结核病

笔记：复旦大学附属里山的医院臧荣余大学教授等

简短：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈肿腺根治病态子宫切除术后基本功能疗程里的序贯放低剂量对比单独放疗或同步放低剂量（STARS研究工作）：一项随机、依此、新开表单的III期试验病态。

内阁会议：外科结核病

笔记：北京大学禁毒里心黄鹤大学教授、刘继红大学教授等

简短号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：基本功能吉非替尼对比低剂量可用可切除的EGFR突变的N1-N2期NSCLC-随机III期病理试验病态的最终各个方面生存环境分析。

专题：肺肿腺—非小细胞核均匀分布-周围/小细胞核/其他胸部

笔记：广东省团结的医院吴一龙大学教授等

简短号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变少移到非小细胞核肺肿腺症状中卫过氧化物丝氨酸衍生物共同或不共同积极前线均匀分布放疗：III期新开表单病理随机试验病态（SINDAS）的里期结果（NCT02893332）。

专题：肺肿腺-非小细胞核移到

笔记：四川省团结的医院曾铭大学教授等

简短：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序病态幸存者-1（PD-1）的人源化IgG4酵母菌共同阿昔替尼可用移到病态黏膜乳癌症状的Ib期研究工作的总生存环境期和生物遥相呼应分析。

专题：乳癌/皮肤肿腺

笔记：北京大学的医院郭军、盛锡楠大学教授等

简短：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全病态和结果：通用CAR-T细胞核首次化学物质试验病态疗程患上/难治病态T细胞核急病态胸腺核白血病（r/r T-ALL）的安全病态和。内阁会议：开发里的疗程技术开发-免疫疗程。笔记：君林欣等简短：3013广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在后期食管突起细胞核肿腺症状里的应用：一项随机的新开表单II期试验病态（ORIENT-2）。内阁会议：消化系统肿腺-消化道食管肿腺、凋亡肿腺和绝道肿腺笔记：徐建明大学教授等简短：4511广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异病态CAR-T细胞核对子叶母细胞核腺的遏止病态疗程内阁会议：里枢神经系统笔记：代红久、孙斌、杨东、徐晖、潘晶晶、魏佳、赵旭东简短：2522广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后期错配修复局限病态症状里的应用内阁会议：开发里的疗程学-免疫疗程笔记：沈琳大学教授等简短：3021广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART疗程患上/难治病态ACUTE胸腺核白血病/癌症的首开化学物质病理试验病态内阁会议: 开发病态疗程学-免疫疗程笔记简介：张明志，板桥乡等简短：3026广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）共同应可用后期实体腺症状的Ib期研究工作内阁会议：发展病态疗程学----分子靶向药物和生物学笔记：龚继芳，沈琳大学教授等简短：3523广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin共同紫杉醇和nedaplatin疗程患上病态或移到病态食管突起细胞核肿腺（ESCC）症状的II期研究工作。内阁会议：消化系统肿腺-消化道食管、凋亡和绝道肿腺的研究工作笔记：君志强，杨玉红，君德申，君凤华，任超，谭琼 君志强、杨玉红、君德深、君凤华、任超、谭琼简短：4522广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.内阁会议：消化系统肿腺-消化道食管肿腺、凋亡肿腺和绝管肿腺的二线疗程笔记：宋艳等简短：4524广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿外体外环RNA线病态可用初始活检时检测高等级肿腺的尿外体外环RNA线病态：一项多里心的回顾病态研究工作内阁会议：泌尿胎盘结核病--------肿腺、睾丸肿腺和肿腺笔记简介：Liaoyuan Li等简短：5522广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 均匀分布后期宫颈肿腺比方说低剂量后的基本功能低剂量内阁会议: 外科结核病笔记简介： 杨珉珉等简短：6031广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗程甲状腺子叶病态肿腺的相关病态：基于ALTER01031试验病态的分析。会话：多毛笔记：天津市团结政府的医院老练大学教授简短：6526广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼疗程后症状结局的影响: ALTER01031的亚组分析内阁会议：多毛笔记：天津市团结政府的医院老练大学教授简短：6527广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA分析预测I-IIIA期非小细胞核肺肿腺（NSCLC）症状术后患上: GASTO1035和GASTO1018的结果内阁会议：肺肿腺-非小细胞核均匀分布-周围病态/小细胞核/小细胞核/其他胸科结核病笔记：Si-Yu Wang等简短：9023广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞核肺肿腺（NSCLC）里EGFR过氧化物丝氨酸衍生物的另行型细菌病态机制内阁会议:肺肿腺-非小细胞核移到病态肺肿腺笔记简介：赵昕，金艾利，满宇，欧秋香，华宝，薛武，杨少，范敏 赵昕、金艾利、满宇、欧秋香、华宝、薛武、杨绍、范敏简短：9528广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验病态里后期乳癌总生存环境的替代终点内阁会议：乳癌/皮肤肿腺笔记：聂润聪，袁书强，杨元芳，陈英波，周志伟 聂润聪、袁书强、杨元芳、陈英波、周志伟简短：10030广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗程患上或移到病态细菌病态恶病态骨症状的II期研究工作内阁会议： 病态疾病笔记：唐丽娜，牛晓辉，君震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、君振、蔡启庆、涂崇奇、范正福、杨瑶简短：11525广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在后期病态疾病症状多线疗程里的安全病态和。内阁会议：病态疾病笔记：姚伟涛，来由强，姚，君林，杜另行辉，田志浩，牛晓颖 姚伟涛、来由强、姚、君鑫、杜鑫辉、田志超、牛晓英简短：11526广告：414